A promising gene therapy for moderate Alzheimer's, developed over 14 years ago at the Cajal Institute of the Spanish National Research Council (CSIC) in Madrid, is set to begin human testing in Australia. The biotech company Tetraneuron obtained authorization from Australian health authorities to initiate the first early-phase study of this therapy, designated TET-101, in humans.
The gene therapy was born in Spain and demonstrated improvements in memory and neuroinflammation in pre-clinical studies. This milestone represents the transition from laboratory research to clinical application in patients.
The clinical trial will initially be conducted at St Vincent's Hospital in Melbourne, Australia. This collaboration between Spanish research and Australian clinical application marks a significant step in the development of new therapeutic options for Alzheimer's.
